NCT03635255 Circulating microRNAs and Adverse Cardiovascular Outcomes in Patients With Coronary Artery Disease
| NCT ID | NCT03635255 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | miRNA |
| Study Type | OBSERVATIONAL |
| Enrollment | 460 participants |
| Start Date | 2019-09-24 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 460 participants in total. It began in 2019-09-24 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Coronary artery disease (CAD) resulting from atherosclerotic obstruction of epicardial coronary arteries accounts for more than one-third of deaths in subjects over the age of 35 worldwide. The global incidence of CAD is on the rise owing to the international epidemic of obesity, type 2 diabetes and aging, all of which are potent risk factors for coronary atherosclerosis. Participants with CAD are at high risk for subsequent adverse cardiovascular (CV) events and death; it has been estimated that one out of every five CAD patients will experience at least one adverse CV event during a 5-year follow up period. There is, however, no reliable diagnostic tool to predict the risk of adverse CV events or death in participanrs with CAD. Increasing evidence suggests that miRNAs are stably present in serum, plasma, urine, saliva and other body fluids and are considered a novel class of non-invasive biomarkers for various diseases including cancer, neurodegenerative and cardiovascular diseases
Eligibility Criteria
Inclusion Criteria: 1. Male or female older than 20 years old. 2. Have a history of cardiovascular disease (including coronary heart disease, or peripheral vascular disease) Exclusion Criteria: Significant valvular or congenital heart disease, cancer, immunosuppressive therapy, or other conditions or treatment your physician thinks you have
Contact & Investigator
Chau chung Wu, PhD
PRINCIPAL INVESTIGATOR
National Taiwan University Hospital
Frequently Asked Questions
Who can join the NCT03635255 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying miRNA. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03635255 currently recruiting?
Yes, NCT03635255 is actively recruiting participants. Contact the research team at Chauchungwu@ntu.edu.tw for enrollment information.
Where is the NCT03635255 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT03635255 clinical trial?
NCT03635255 is sponsored by National Taiwan University Hospital. The principal investigator is Chau chung Wu, PhD at National Taiwan University Hospital. The trial plans to enroll 460 participants.